ARCTURUS THERAPEUTICS HOLDINGS INC. Income (Loss) from Equity Method Investments
ARCTURUS THERAPEUTICS HOLDINGS INC. (ARCT) reported Income (Loss) from Equity Method Investments of -$515.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2025-03-06.
Financial Statements › Income Statement › Other Income
us-gaap:IncomeLossFromEquityMethodInvestments · last filed 2025-03-06
- ARCTURUS THERAPEUTICS HOLDINGS INC. income (loss) from equity method investments for the quarter ending 2022-12-31 was $0.00.
- ARCTURUS THERAPEUTICS HOLDINGS INC. income (loss) from equity method investments for the quarter ending 2022-09-30 was $0.00.
- ARCTURUS THERAPEUTICS HOLDINGS INC. income (loss) from equity method investments for the quarter ending 2022-06-30 was -$131.00K.
- ARCTURUS THERAPEUTICS HOLDINGS INC. income (loss) from equity method investments for the quarter ending 2022-03-31 was -$384.00K, a 130.77% decline year-over-year.
- ARCTURUS THERAPEUTICS HOLDINGS INC. income (loss) from equity method investments for fiscal 2022 was -$515.00K, a 200.00% decline from fiscal 2021.
- ARCTURUS THERAPEUTICS HOLDINGS INC. income (loss) from equity method investments for fiscal 2021 was $515.00K.
- ARCTURUS THERAPEUTICS HOLDINGS INC. income (loss) from equity method investments for fiscal 2020 was -$263.00K.
- ARCTURUS THERAPEUTICS HOLDINGS INC. income (loss) from equity method investments for fiscal 2019 was -$32.00K.
| Period end | Income (Loss) from Equity Method Investments 3 month | Income (Loss) from Equity Method Investments 6 month | Income (Loss) from Equity Method Investments 9 month | Income (Loss) from Equity Method Investments 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $0.00 derived: sum of 2 quarters · filed 2025-03-06 | -$131.00K derived: sum of 3 quarters · filed 2025-03-06 | -$515.00K 10-K · filed 2025-03-06 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$131.00K derived: sum of 2 quarters · filed 2023-11-14 | -$515.00K 10-Q · filed 2023-11-14 | -$670.00K derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-06-30 | -$131.00K 10-Q · filed 2023-08-07 | -$515.00K 10-Q · filed 2023-08-07 | -$670.00K derived: sum of 3 quarters · filed 2024-03-14 | -$920.00K derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-03-31 | -$384.00K 10-Q · filed 2023-05-09 | -$539.00K derived: sum of 2 quarters · filed 2024-03-14 | -$789.00K derived: sum of 3 quarters · filed 2024-03-14 | -$1.12M derived: sum of 4 quarters · filed 2024-03-14 |
| 2021-12-31 | -$155.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$405.00K derived: sum of 2 quarters · filed 2024-03-14 | -$733.00K derived: sum of 3 quarters · filed 2024-03-14 | $515.00K 10-K · filed 2024-03-14 |
| 2021-09-30 | -$250.00K 10-Q · filed 2022-11-09 | -$578.00K derived: sum of 2 quarters · filed 2022-11-09 | $670.00K 10-Q · filed 2022-11-09 | $670.00K derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | -$328.00K 10-Q · filed 2022-08-09 | $920.00K 10-Q · filed 2022-08-09 | $920.00K derived: sum of 3 quarters · filed 2022-08-09 | $920.00K derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $1.25M 10-Q · filed 2022-05-09 | $1.25M derived: sum of 2 quarters · filed 2022-05-09 | $1.25M derived: sum of 3 quarters · filed 2022-05-09 | $1.15M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $0.00 derived: sum of 2 quarters · filed 2022-03-01 | -$100.00K derived: sum of 3 quarters · filed 2022-03-01 | -$263.00K 10-K · filed 2022-03-01 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | -$100.00K derived: sum of 2 quarters · filed 2021-11-09 | -$263.00K 10-Q · filed 2021-11-09 | -$310.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | -$100.00K 10-Q · filed 2021-08-10 | -$263.00K 10-Q · filed 2021-08-10 | -$310.00K derived: sum of 3 quarters · filed 2022-03-01 | -$7.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | -$163.00K 10-Q · filed 2021-05-10 | -$210.00K derived: sum of 2 quarters · filed 2022-03-01 | $93.00K derived: sum of 3 quarters · filed 2022-03-01 | $93.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | -$47.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $256.00K derived: sum of 2 quarters · filed 2022-03-01 | $256.00K derived: sum of 3 quarters · filed 2022-03-01 | -$32.00K 10-K · filed 2022-03-01 |
| 2019-09-30 | $303.00K 10-Q · filed 2020-11-09 | $303.00K derived: sum of 2 quarters · filed 2020-11-09 | $15.00K 10-Q · filed 2020-11-09 | -$240.00K derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | -$288.00K 10-Q · filed 2020-08-10 | -$543.00K derived: sum of 3 quarters · filed 2021-03-01 | -$590.00K derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | -$288.00K 10-Q · filed 2020-05-08 | -$543.00K derived: sum of 2 quarters · filed 2021-03-01 | -$590.00K derived: sum of 3 quarters · filed 2021-03-01 | -$637.00K derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | -$255.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$302.00K derived: sum of 2 quarters · filed 2021-03-01 | -$349.00K derived: sum of 3 quarters · filed 2021-03-01 | -$302.00K 10-K · filed 2021-03-01 |
| 2018-09-30 | -$47.00K 10-Q · filed 2019-11-08 | -$94.00K derived: sum of 2 quarters · filed 2019-11-08 | -$47.00K 10-Q · filed 2019-11-08 | |
| 2018-06-30 | -$47.00K 10-Q · filed 2019-08-14 | -$47.00K 10-Q · filed 2019-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |